March 10, 2008, Research Triangle Park, NC--Bioptigen has been awarded the Frost & Sullivan 2008 North American Excellence in Research Award for its work in spectral-domain optical coherence tomography (SD-OCT) for ophthalmology.
'Bioptigen is honored to receive this recognition from Frost & Sullivan for our developments in spectral domain optical coherence tomography (SDOCT). We are particularly proud of the dedication and passion of the talented team responsible for our progress,' commented Eric Buckland, co-founder and Chief Executive Officer of Bioptigen, Inc.
"Bioptigen and our collaborators in academia and industry recognize the importance of our SD-OCT implementation to pre-clinical research and development as well as to the clinical diagnosis of disease at its very earliest stages," said Eric Buckland, co-founder and CEO of Bioptigen.
Dr. Joseph Izatt, Bioptigen' s co-founder and CTO and Professor of Biomedical Engineering and Ophthalmology at Duke University, added, "This recognition is validation of our vision for the current and future potential of SD-OCT. Our emphasis looking forward is to extend the capabilities of our systems for functional imaging, and to search for new biomarkers of disease processes that will be uniquely accessible through the power of SD-OCT."
According to Frost & Sullivan analyst Rasika Ramachandran, Bioptigen's OCT imaging system is distinguished by demonstrably superior image quality, real time acquisition, processing and display, and a very high degree of flexibility.
"The company provides research-grade equipment into markets as diverse as ophthalmology, oncology, orthopedics, and genomics, with flexibility in delivery optics and software," Ramachandran said. "At the same time, their platform can be rapidly configured for ease of use in clinical diagnostics. With the unique performance and flexibility of their system, Bioptigen and its technology are poised for success."